There’s No Escaping Arcus Biosciences, Inc.’s (NYSE:RCUS) Muted Revenues Despite A 28% Share Price Rise
Arcus Biosciences, Inc. (NYSE:RCUS) shareholders would be excited to see that the share price has had a great month, posting a 28% gain and recovering from prior weakness. Not all shareholders will be feeling jubilant, since the share price is still down a very disappointing 22% in the last twelve months.
Even after such a large jump in price, Arcus Biosciences may still be sending bullish signals at the moment with its price-to-sales (or “P/S”) ratio of 5x, since almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 9.2x and even P/S higher than 69x are not unusual. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the reduced P/S.
